DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1064664
Title:
A Vaccine to Prevent Leishmaniasis
Corporate Author:
BAYLOR COLL OF MEDICINE HOUSTON TX HOUSTON United States
Report Date:
2018-10-01
Abstract:
Building on extensive preliminary data and an established consortium of academic, government, military, and product development partners, we propose to develop a production process for a novel, bivalent vaccine against leishmaniasis, a serious neglected tropical disease NTD of military and civilian personnel now spreading rapidly in conflict zones of the Middle East and Central Asia. The proposed Cutaneous Leishmania Vaccine CL-Vax is a bivalent, recombinant protein-based vaccine that will be comprised of a specific Leishmania parasite antigen together with a novel sand fly salivary antigen, co-administered at bedside with an adequate adjuvant. The components of the vaccine will be extensively characterized, and their immunogenicity and efficacy will be confirmed in animal models.
Descriptive Note:
Technical Report,15 Sep 2017,14 Sep 2018
Pages:
0033
Distribution Statement:
Approved For Public Release;
File Size:
3.20MB
